Additionally, a retrospective study (52) of EGFR-mutant NSCLC patients with brain metastases showed that when compared with previous whole-brain radiotherapy (WBRT) or EGFR-TKIs, SRS after treatment with TKIs achieved longer survival, and the median OS in SRS, WBRT, and EGFR-TKIs cohorts were 46, 30, and 25 months, respectively (P=0.001). This evidence concerns the gene EGFR and non-small cell lung carcinoma.